Transparency and the reporting of subgroup analyses by Guehring and colleagues
- PMID: 34134895
- DOI: 10.1016/j.semarthrit.2021.05.002
Transparency and the reporting of subgroup analyses by Guehring and colleagues
Comment in
-
Response letter to the Editor.Semin Arthritis Rheum. 2022 Feb;52:151839. doi: 10.1016/j.semarthrit.2021.05.001. Epub 2021 May 8. Semin Arthritis Rheum. 2022. PMID: 34006385 No abstract available.
Comment on
-
The effects of sprifermin on symptoms and structure in a subgroup at risk of progression in the FORWARD knee osteoarthritis trial.Semin Arthritis Rheum. 2021 Apr;51(2):450-456. doi: 10.1016/j.semarthrit.2021.03.005. Epub 2021 Mar 11. Semin Arthritis Rheum. 2021. PMID: 33752164 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources